Search Results - "LESIMPLE, T."

Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapy by Servy, A., Maubec, E., Sugier, P.E., Grange, F., Mansard, S., Lesimple, T., Marinho, E., Couturaud, B., Girod, A., Albert, S., Dendale, R., Calitchi, E., Sarda, L., Chanal, J., Deschamps, L., Sastre-Garau, X., Laroche, L., Crickx, B., Avril, M.F.

“…Sentinel lymph-node (LN) biopsy (SLNB) is a valuable tool to assess the regional LN status in Merkel cell carcinoma (MCC). However, its prognostic value is…”
Get full text

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort by Kandel, M., Allayous, C., Dalle, S., Mortier, L., Dalac, S., Dutriaux, C., Leccia, M.T., Guillot, B., Saiag, P., Lacour, J.P., Legoupil, D., Lesimple, T., Aubin, F., Beylot-Barry, M., Brunet-Possenti, F., Arnault, J.P., Granel-Brocard, F., Stoebner, P.E., Dupuy, A., Maubec, E., Grob, J.J., Dreno, B., Rotolo, F., Ballon, A., Michiels, S., Lebbe, C., Borget, I.

“…Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which…”
Get full text

Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data by Di Filippo, Y., Dalle, S., Mortier, L., Dereure, O., Dalac, S., Dutriaux, C., Leccia, M.-T., Legoupil, D., Saiag, P., Brunet-Possenti, F., Arnnault, J.-P., Maubec, E., Granel-Brocard, F., De Quatrebarbes, J., Aubin, F., Lesimple, T., Beylot-Barry, M., Stoebner, P.-E., Dupuy, A., Stephan, A., Grob, J.-J., Lefevre, W., Oriano, B., Allayous, C., Lebbé, C., Montaudié, H.

“…The ‘obesity paradox’ suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those…”
Get full text

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study by Mouriaux, F, Servois, V, Parienti, J J, Lesimple, T, Thyss, A, Dutriaux, C, Neidhart-Berard, E M, Penel, N, Delcambre, C, Peyro Saint Paul, L, Pham, A D, Heutte, N, Piperno-Neumann, S, Joly, F

“…Background: The aim of the study was to analyse efficacy, safety, and health-related quality of life (HRQoL) for sorafenib treatment in patients with…”
Get full text

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer by Fumoleau, P., Largillier, R., Clippe, C., Dièras, V., Orfeuvre, H., Lesimple, T., Culine, S., Audhuy, B., Serin, D., Curé, H., Vuillemin, E., Morère, J.-F., Montestruc, F., Mouri, Z., Namer, M.

“…Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC) represents a significant challenge to oncologists. The…”
Get full text

An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma by Saiag, P., Robert, C., Grob, J.J., Mortier, L., Dereure, O., Lebbe, C., Mansard, S., Grange, F., Neidhardt, E.-M., Lesimple, T., Machet, L., Bedane, C., Jeudy, G., Aubin, F., Dreno, B., Szenik, A., Denden, A., Dutriaux, C.

Get full text

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study by Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F

“…PurposeThe PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed…”
Get full text

Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma by Pracht, M., Mogha, A., Lespagnol, A., Fautrel, A., Mouchet, N., Le Gall, F., Paumier, V., Lefeuvre-Plesse, C., Rioux-Leclerc, N., Mosser, J., Oger, E., Adamski, H., Galibert, M.-D., Lesimple, T.

“…Background Mutations of BRAF, NRAS and c‐KIT oncogenes are preferentially described in certain histological subtypes of melanoma and linked to specific…”
Get full text

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study by Charton, E., Baldini, C., Fayet, Y., Schultz, E., Auroy, L., Vallier, E., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Touzeau, C., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.-J., Delord, J.-P., Gomez Roca, C., Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.-C., Massard, C., Besle, S.

“…Investigation of the disparities in the access to experimental treatment in early-phase clinical trials is lacking. The objective of the EGALICAN-2 study was…”
Get full text

Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase by Allayous, C., Oriano, B., Dalle, S., Mortier, L., Leccia, M.-T., Guillot, B., Jeudy, G., Dutriaux, C., Lacour, J.-P., Saiag, P., Brunet-Possenti, F., De Quatrebarbes, J., Stoebner, P.-E., Legoupil, D., Beylot-Barry, M., Lesimple, T., Aubin, F., Ballon, A., Porcher, R., Lebbe, C.

Get full text

Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma by Mignard, C., Deschamps-Huvier, A., Duval-Modeste, A.-B., Dutriaux, C., Khammari, A., Avril, M.-F., Mortier, L., Lesimple, T., Gaudy-Marqueste, C., Lesage, C., Machet, L., Aubin, F., Meyer, N., Beneton Benhard, N., Jeudy, G., Montaudié, H., Arnault, J.-P., Leccia, M.-T., Joly, P., Oncology Research Group Of The French Society Of Dermatology, S.F.D.

Get full text

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study by Baldini, C., Charton, E., Schultz, E., Auroy, L., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Le Gouill, S., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.J., Delord, J.P., Roca, C. Gomez, Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.C., Massard, C., Besle, S.

“…Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related…”
Get full text

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial by Gross-Goupil, M, Fourcade, A, Blot, E, Penel, N, Négrier, S, Culine, S, Chaigneau, L, Lesimple, T, Priou, F, Lortholary, A, Kaminsky, M.C, Provencal, J, Voog, E, Bouzy, J, Laplanche, A, Fizazi, K

“…Abstract Purpose To compare the overall survival rates of good-prognosis carcinomas of an unknown primary site (CUPS) patients treated with cisplatin alone (C)…”
Get full text

Leiomyosarcoma of the inferior vena cava by Sulpice, L, Rayar, M, Levi Sandri, G.-B, de Wailly, P, Henno, S, Turner, K, Lesimple, T, Boudjema, K, Meunier, B

“…Summary Background Leiomyosarcoma (LMS) of the inferior vena cava (IVC) is a rare tumor with poor prognosis. Optimal treatment includes complete resection of…”
Get full text

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil by Negrier, S, Caty, A, Lesimple, T, J-Y, Douillard, Escudier, B, J-F, Rossi, Viens, P, Gomez, F

“…Purpose: Subcutaneous recombinant interleukin-2 (rIL-2) and recombinant interferon alfa-2a (rIFNalpha-2a) have been used extensively in the treatment of…”
Get full text

431 Real-time pharmacokinetic (PK) results from an ongoing randomized, parallel-dose phase 1 study of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers by Lokiec, F, Bonneterre, J, Italiano, A, Varga, A, Campone, M, LeSimple, T, Leary, A, Dieras, V, Rezai, K, Giacchetti, S, Proniuk, S, Bexon, A, Gilles, E, Bisaha, J, Zukiwski, A, Cottu, P

Get full text

Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial by By the French Adjuvant Study Group

“…To determine the influence of the epirubicin dose in operable node-positive breast cancer patients with factors of poor prognosis. Between April 1990 and July…”
Get full text

604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial by Awada, A, Delord, J.P, Houédé, N, Lebbe, C, Lesimple, T, Schellens, J.H.M, Rottey, S, Kefford, R, Rejeb, N, Raymond, E

Get full text

616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma by Delord, J.P, Houédé, N, Awada, A, Lebbe, C, Lesimple, T, Schellens, J.H.M, Rottey, S, Kefford, R, Rejeb, N, Raymond, E

Get full text

Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15 patients by Chabbert, C., Adamski, H., Guillet, G., Sassolas, B., Misery, L., Perrinaud, A., Machet, L., Quereux, G., Esteve, E., Solau-Gervais, E., Saraux, A., Polard, E., Lesimple, T., Le Gall, F., Dreno, B., Dupuy, A.

“…Background Several case reports suggested that tumour necrosis factor‐α (TNF) inhibitors might increase the incidence and/or alter the natural course of…”
Get full text